en
Scientific article
Open access
English

Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma

Published inBritish journal of cancer, vol. 110, no. 11, p. 2655-2661
Publication date2014
Abstract

Sorafenib (Sb) is a multiple kinase inhibitor targeting both tumour cell proliferation and angiogenesis that may further act as a potent radiosensitizer by arresting cells in the most radiosensitive cell cycle phase. This phase I open-label, noncontrolled dose escalation study was performed to determine the safety and maximum tolerated dose (MTD) of Sb in combination with radiation therapy (RT) and temozolomide (TMZ) in 17 patients with newly diagnosed high-grade glioma.

Keywords
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics/therapeutic use/toxicity
  • Brain Neoplasms/mortality/therapy
  • Chemoradiotherapy
  • Dacarbazine/administration & dosage/analogs & derivatives
  • Disease-Free Survival
  • Female
  • Glioblastoma/mortality/therapy
  • Humans
  • Male
  • Maximum Tolerated Dose
  • Middle Aged
  • Niacinamide/administration & dosage/analogs & derivatives
  • Phenylurea Compounds/administration & dosage
  • Treatment Outcome
Citation (ISO format)
HOTTINGER, A F et al. Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma. In: British journal of cancer, 2014, vol. 110, n° 11, p. 2655–2661. doi: 10.1038/bjc.2014.209
Main files (1)
Article (Published version)
Updates (1)
Identifiers
ISSN of the journal0007-0920
458views
99downloads

Technical informations

Creation01/05/2017 7:00:00 PM
First validation01/05/2017 7:00:00 PM
Update time03/15/2023 1:16:13 AM
Status update03/15/2023 1:16:13 AM
Last indexation10/19/2023 2:58:35 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack